Canaccord lowered the firm’s price target on PacBio to $3.50 from $10 and keeps a Buy rating on the shares. The firm said although they remain constructive, their confidence has declined following the company’s alarmingly large 1Q24 miss and cut to 2024 and long-term revenue guidance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance
- Cathie Wood’s ARK Investment bought 349K shares of PacBio today
- PacBio price target lowered to $3 from $8 at Barclays
- Cathie Wood’s ARK Investment bought 190K shares of PacBio today
- Cathie Wood’s ARK Investment bought 273K shares of PacBio today
